Evaluation of the Efficacy and Tolerability of Detralex in Patients With Chronic Venous Edema in Real Clinical Practice

Exclusion Criteria

• •Age below 18 years old
• •Written informed consent is not obtained
• •History of alcohol or drug abuse or use of narcotic drugs
• •History of allergic reaction to diosmin or any other venoactive agent, or their intolerance
• •History of allergic reaction to anesthetics and/or sclerosing agents
• •Chronic venous disease of СЕАР class C0-С2 or class С4-С6
• •Lymphatic edema of the lower extremities
• •Secondary varicose veins, angiodysplasia, or neoplasia
• •Arterial disease (ankle-brachial index \<0.9)
• •Infection within the past 6 weeks
• •Any of the following concomitant diseases, which can affect the results:
• •* Connective tissue disease (including rheumatoid arthritis), arthritis
• •* Heart failure
• •* Intermittent claudication (peripheral artery disease)
• •* Diseases of the bones or joints of the lower extremities
• •* Malignancy
• •Treatment with drugs potentially causing leg edema (calcium channel blockers, hormonal drugs, NSAIDs, etc.)
• •History of deep vein thrombosis (within the past year)
• •History of superficial thrombophlebitis (within the past 3 months)
• •Patient cannot walk (regardless of the cause)
• •Obesity or body mass index \[BMI\] \>30 kg/m2 \[BMI = body mass (kg)/height (m)2\]
• •Predictable poor adherence to treatment
• •Participation of the patient in the intervention study within the previous 3 months
• •For women: pregnancy or breastfeeding, the desire to become pregnant within at least 2 months after the study
• •Patient cannot attend a follow-up visit
• •Patients with a contraindication to diosmin-containing agents, including Detralex